Priya Kumar, MD
Hematology & Oncology · Stillwater, MNNPI 1578501847
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $41,162 of the $47,768 with a category attached, or 86.2%. 7 manufacturers reported payments, led by Daiichi Sankyo Inc. at 48.8% of the total. Among hematology & oncology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 52 payments — averaging $918.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$23K
- AstraZeneca$17K
- Avyxa Pharma, LLC$4K
- Sanofi$2K
- Incyte Corporation$860
- Blueprint Medicines Corporation$788
- plus $19 from 1 others
Across 16 payments — averaging $6666.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$107K
What the payments were for
- Consulting fees$41,16286%
- Speaking & faculty fees$2,5505%
- Travel & lodging$3,0266%
- Food & beverage$1,0112%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 15 | $23,320 |
| AstraZeneca | 22 | $16,834 |
| Avyxa Pharma, LLC | 8 | $4,171 |
| Sanofi | 4 | $1,775 |
| Incyte Corporation | 1 | $860 |
| Blueprint Medicines Corporation | 1 | $788 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,768 in reported general payments places this provider in the 90th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 27 | $353,249 |
| RevlimidLenalidomide | 11 | $265,899 |
| LenvimaLenvatinib Mesylate | 11 | $249,205 |
| KisqaliRibociclib Succinate | 12 | $213,717 |
| InlytaAxitinib | 12 | $185,958 |
| VenclextaVenetoclax | 12 | $176,192 |
| BrukinsaZanubrutinib | 12 | $160,694 |
| Everolimus | 24 | $122,891 |
| XareltoRivaroxaban | 72 | $77,345 |
| EliquisApixaban | 65 | $59,373 |
| Abiraterone Acetate | 70 | $17,760 |
| CreonLipase/Protease/Amylase | 11 | $11,262 |
| Tamoxifen Citrate | 119 | $3,960 |
| Anastrozole | 159 | $3,266 |
| Exemestane | 29 | $2,501 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Stillwater
- Mark RedingMinneapolis$519K
- Shilpa GuptaMinneapolis$421K
- Sagar PatelEdina$389K
- Vicki MorrisonMinneapolis$354K
- Deepti BehlRochester$205K
- Yan JiSaint Paul$164K
- Aimee MerinoMinneapolis$161K
- Yucai WangRochester$77K
- Purvi GadaChaska$76K
- Julia BakerDuluth$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.